Skip to main content
. 2016 May 17;1(3):e000045. doi: 10.1136/esmoopen-2016-000045

Figure 4.

Figure 4

OS of patients with colorectal cancer with grade 2–3 bevacizumab-induced HTN and without bevacizumab-related HTN (p 0.114). HTN, hypertension; OS, overall survival.